| Wissenschaftl. Titel | A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3) |
| Erkrankung |
Gastro:
Leberzellkarzinom:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (HD) Weiterführende Informationen (NIH) |
erstellt 28.08.2024 Data entry III CCP
geändert 17.10.2024 Data entry III CCP